GlaxoSmithKline Pharmaceuticals Limited has received a certificate regarding the dematerialization of securities for the quarter ended September 30, 2025. The registrar and share transfer agent, Kfin Technologies Limited, confirmed that securities received for dematerialization have been processed and that necessary updates have been made to the register of members. This announcement was made on October 8, 2025.
Dematerialization Certificate Received
GlaxoSmithKline Pharmaceuticals Limited has received confirmation regarding the handling of securities during the quarter ending September 30, 2025. Kfin Technologies Limited, the registrar and share transfer agent, provided the certificate.
Key Points of the Certificate
The certificate confirms that all securities received for dematerialization during Q2 (Jul-Sep) 2025 have been duly processed. The depositories have accepted or rejected the securities as appropriate. Furthermore, the security certificates received for dematerialization have been mutilated and cancelled after verification. The names of the depositories have been updated in the register of members.
This announcement was officially released on October 8, 2025.
Source: BSE
